Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1646 1674
This examiner grants 56% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17470455 | BIOMARKERS AND METHODS FOR ASSESSING PSORIATIC ARTHRITIS DISEASE ACTIVITY | Final Rejection | The Regents of the University of California |
| 18101310 | Dosing Strategy that Mitigates Cytokine Release Syndrome for Therapeutic Antibodies | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 18045588 | ANTIBODIES TO HUMAN GDF8 | Final Rejection | Regeneron Pharmaceuticals, Inc. |
| 19312167 | Compositions and Methods of Treatment for Various Conditions using High-Molecular Weight Hyaluronic Acid | Final Rejection | Embrient, Inc. |
| 17771313 | COMPOSITIONS AND METHODS FOR MINIMIZING PROTEIN LOSS AT LOW PROTEIN CONCENTRATIONS | Final Rejection | AMGEN INC. |
| 18019052 | CST6, CELLS EXPRESSING CST6 AND METHODS OF USE | Non-Final OA | BioVentures, LLC |
| 18653312 | COMPOSITIONS AND METHODS FOR TARGETING CD99-EXPRESSING CANCERS | Non-Final OA | H. Lee Moffitt Cancer Center and Research Institute, Inc. |
| 17772042 | Immune Response Suppressant | Final Rejection | University of Tsukuba |
| 17432177 | LIF THERAPY FOR INDUCING INTESTINAL EPITHELIAL CELL REGENERATION | Non-Final OA | Rutgers, the State University of New Jersey |
| 17615959 | ANTI-TNF ANTIBODIES, COMPOSITIONS, AND METHODS FOR THE TREATMENT OF ACTIVE ANKYLOSING SPONDYLITIS | Final Rejection | Janssen Biotech, Inc. |
| 18435494 | MULTI SPECIFIC MOLECULES | Non-Final OA | AFFILOGIC |
| 18319821 | Treatment of ENPP1 Deficiency and ABCC6 Deficiency | Non-Final OA | Inozyme Pharma, Inc. |
| 18248729 | MODIFIED INTERLEUKIN 2 (IL-2) POLYPEPTIDES, AND METHODS OF MAKING AND USING THE SAME | Non-Final OA | CYTIMM THERAPEUTICS, INC. |
| 18016752 | METHOD FOR SCREENING COLORECTAL CANCER METASTASIS INHIBITOR | Final Rejection | FNCT BIOTECH, INC. |
| 17871180 | METHODS OF STIMULATING BONE GROWTH WITH ABALOPARATIDE AND DENOSUMAB | Non-Final OA | Radius Health, Inc. |
| 17429297 | USE OF ACTIVATORS OF THE ARYL HYDROCARBON RECEPTOR FOR TREATING GLUTEN-INDUCED GASTROINTESTINAL DISEASES | Non-Final OA | Institut National De Recherche Pour L'Agriculture, L'Alimentation et I'Environnement |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy